Market closedNon-fractional
Ocular Therapeutix/OCUL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ticker
OCUL
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Bedford, United States
Employees
267
Website
www.ocutx.com
OCUL Metrics
BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$1.30
EPS
1.46
Beta
-
Dividend rate
Price and volume
Market cap
$1.3B
Beta
1.46
Financial strength
Current ratio
21.394
Quick ratio
20.966
Long term debt to equity
17.859
Total debt to equity
18.237
Interest coverage (TTM)
-6.71%
Management effectiveness
Return on assets (TTM)
-17.12%
Return on equity (TTM)
-55.19%
Valuation
Price to revenue (TTM)
12.935
Price to book
3.14
Price to tangible book (TTM)
3.14
Price to free cash flow (TTM)
-8.886
Growth
Revenue change (TTM)
15.79%
Earnings per share change (TTM)
8.70%
3-year revenue growth (CAGR)
39.31%
3-year earnings per share growth (CAGR)
-17.59%
What the Analysts think about OCUL
Analyst Ratings
Majority rating from 8 analysts.
OCUL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$15M
-0.68%
Net income
-$65M
121.92%
Profit margin
-440.81%
123.43%
OCUL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.26
-$0.01
-$0.35
-$0.49
-
Expected
-$0.30
-$0.29
-$0.30
-$0.19
-$0.22
Surprise
-13.91%
-96.52%
15.13%
155.97%
-
OCUL News
AllArticlesVideos
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
GlobeNewsWire·2 weeks ago
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocular Therapeutix stock?
Ocular Therapeutix (OCUL) has a market cap of $1.3B as of July 27, 2024.
What is the P/E ratio for Ocular Therapeutix stock?
The price to earnings (P/E) ratio for Ocular Therapeutix (OCUL) stock is 0 as of July 27, 2024.
Does Ocular Therapeutix stock pay dividends?
No, Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ocular Therapeutix dividend payment date?
Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocular Therapeutix?
Ocular Therapeutix (OCUL) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Ocular Therapeutix stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.